LigandAI

LigandAI is an advanced predictive interactomics platform designed for the accelerated creation of tissue-specific binding peptides. This tool leverages a multi-agent AI approach and high-performance GPU computing to transform therapeutic target discovery into high-affinity binder design in a matter of seconds. Its primary function is to assist researchers and bioinformaticians in identifying specific receptors and generating structurally validated therapeutic candidates.

The core technology is powered by LigandForge™, a discrete diffusion model conditioned by the binding pocket that generates peptide sequences based on receptor geometry. Unlike other methods, this system does not require folding within the generation loop, allowing it to reach processing speeds of up to 1,190 sequences per second. Subsequently, the ecosystem integrates Boltz-2 for 3D structure prediction and DeltaForge, a scoring engine developed in Rust that predicts binding affinity ($\Delta G$ and $K_d$) with accuracy validated against experimental data.

The LigandAI workflow covers everything from initial discovery to practical validation:

• Target Identification: The AI analyzes transcriptomic atlases to locate receptors with optimal tissue-specific expression profiles (such as the brain or liver).
• Peptide Generation: Production of over 300 candidates per target through de novo design with multiscale thermodynamic supervision.
• Structural Validation: Utilization of NVIDIA B200 clusters for the concurrent folding of peptide-receptor complexes.
• Integrated Optimization: Modules to adjust immunogenicity and serum stability directly during the diffusion process.

For pharmaceutical and biotech professionals, this tool offers a comprehensive solution for developing targeted gene therapies and novel drugs. The platform has demonstrated its effectiveness across more than 150 human receptor targets, successfully identifying candidates with sub-100 nM affinity in 97% of cases. By combining computational design with biolayer interferometry (BLI) validation, LigandAI drastically reduces development timelines for therapeutic peptides.

The tool is especially valuable for laboratories requiring massive processing capacity and precision in multimeric structure prediction. Its architecture enables automated receptor discovery and the screening of millions of sequences, establishing itself as a high-speed, high-fidelity AI-assisted drug design ecosystem. Ultimately, it is a robust solution for optimizing drug delivery and creating next-generation ligands.